inVentiv Health launches new European shop

Share this article:
49331_ncgsmc_gsw_wht_paper_16

Healthcare marketing agency inVentiv Health has further extended its breadth of services to the European market with the launch of a new shop called inVentiv Health Communications/Europe.

The new agency will be led by Bob Chandler, founder of Chandler Chicco Companies and SVP, marketing and communications at inVentiv Health. Headquartered in London, inVentiv Health Communications/Europe will now encompass previously established inVentiv Euro shops GSW Europe and Junction 11, in addition to the organization's new branch.

“The power of the well-regarded assets of inVentiv Health Communications/Europe, now working in greater unison, will have a profound impact on how we tackle opportunities emerging every day in the evolving European healthcare environment,” said Chandler in a statement. “Our new way of going to market is designed to facilitate a multidisciplinary approach to driving plans and programs that reach intended target audiences with greater speed and relevancy. We believe this efficiency will generate financial savings for our clients.”  

inVentiv Health has also released its Q2 financial information, reportedly earning $220.5 million in net revenue for the company's commercial business as of June 30 this year, a 14% increase since Q2 2010. Part of this sum is accounted for in inVentiv's acquisition of pharma and biotech consulting firm Campbell Alliance, which the company purchased this past February.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.